English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
 Local TagsRelease HistoryDetailsSummary
  A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells

Hartung, F., Krüwel, T., Shi, X., Pfizenmaier, K., Kontermann, R., Chames, P., et al. (2020). A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells. Frontiers in Pharmacology, 11, 686. doi:10.3389/fphar.2020.00686.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/21.11116/0000-0009-F25D-E Version Permalink: https://hdl.handle.net/21.11116/0000-0009-F25E-D
Genre: Journal Article

Files

show Files

Locators

show
hide
Locator:
https://www.ncbi.nlm.nih.gov/pubmed/32528281 (Any fulltext)
Description:
-
OA-Status:

Creators

show
hide
 Creators:
Hartung, Franziska1, Author
Krüwel, Thomas1, Author
Shi, Xiaoyi1, Author
Pfizenmaier, Klaus1, Author
Kontermann, Roland1, Author
Chames, Patrick1, Author
Alves, Frauke1, Author
Pardo, Luis A.1, Author
Affiliations:
1Max Planck Society, ou_persistent13              

Content

show
hide
Free keywords: Kv10.1 Trail apoptosis nanobody targeted therapy voltage-gated potassium channel
 Abstract: Antibody-based therapies hold promise for a safe and efficient treatment of cancer. The identification of target tumor cells through a specific antigen enriched on their surface and the subsequent delivery of the therapeutic agent only to those cells requires, besides the efficacy of the therapeutic agent itself, the identification of an antigen enriched on the surface of tumor cells, the generation of high affinity antibodies against that antigen. We have generated single-domain antibodies (nanobodies) against the voltage-gated potassium channel Kv10.1, which outside of the brain is detectable almost exclusively in tumor cells. The nanobody with highest affinity was fused to an improved form of the tumor necrosis factor-related apoptosis inducing ligand TRAIL, to target this cytokine to the surface of tumor cells. The resulting construct, VHH-D9-scTRAIL, shows rapid and strong apoptosis induction in different tumor models in cell culture. The construct combines two sources of specificity, the expression of the antigen restricted to tumor cells and the tumor selectivity of TRAIL. Such specificity combined with the high affinity obtained through nanobodies make the novel agent a promising concept for cancer therapy.

Details

show
hide
Language(s):
 Dates: 2020-06-13
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: Other: 32528281
DOI: 10.3389/fphar.2020.00686
ISSN: 1663-9812
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Frontiers in Pharmacology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 11 Sequence Number: - Start / End Page: 686 Identifier: -